Sleepiness and Brain Function: The Effect of Armodafinil in Shift Work Sleep Disorder

Brief Summary

Official Title: “Magnetoencephalographic Imaging of Sleepiness: The Effect of Armodafinil in Shift Work Sleep Disorder”

The investigators hypothesize that in patients with shift work sleep disorder, armodafinil will specifically increase brain activity in the frontal cortex parallel with improvements in deficits of fundamental mechanisms of attention.

  • Study Type: Observational
  • Study Design: Time Perspective: Prospective
  • Study Primary Completion Date: March 2010

Detailed Clinical Trial Description

The current protocol will utilize a paradigm which is well suited to examine frontal attentional neuronal mechanisms by eliciting event related potential components known to reflect automatic stimulus detection as well as involuntary and voluntary attentional processes. The that end the proposed research has two specific aims. 1) Identify what areas of the frontal lobe and corresponding cognitive functions are impacted by excessive sleepiness in shift work sleep disorder and 2) identify specific brain areas affected by armodafinil and their role in improvement of fundamental attentional processes using a complex cognitive task targeting attentional control.

Arms, Groups and Cohorts in this Clinical Trial

  • 1
    • Individuals with shift work sleep disorder
  • 2
    • Healthy night shift workers without shift work sleep disorder

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • Night shift workers with and without shift work sleep disorder.

Exclusion Criteria

  • Secondary condition to shift work sleep disorder.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 55 Years

Are Healthy Volunteers Accepted for this Clinical Trial: Accepts Healthy Volunteers

Clinical Trial Investigator Information

  • Lead Sponsor
    • Henry Ford Health System
  • Collaborator
    • Cephalon
  • Provider of Information About this Clinical Study
    • Christopher Drake, Ph.D., Henry Ford Health System
  • Overall Official(s)
    • Christopher Drake, Ph.D., Principal Investigator, Henry Ford Hospital Sleep Disorders & Research Center


Clinical Trials content is provided directly by the US National Institutes of Health via and is not reviewed separately by Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: